Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, a medicine in development that is a monoclonal antibody, targets the epidermal growth factor receptor. Because cancer cells can become dependent on the growth signals that are mediated through the epidermal growth factor receptor, blocking it may stop the growth of cancer cells and eradicate existing cancer cells.

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • New cancer treatments account for large percent of life expectancy gains
     
  • A drug for testicular cancer that cost an estimated $56 million to develop led to a sharp increase in survival rate and an annual return of $166 million in treatment…  
  • According to the Pharmaceutical Research and Manufacturers of America, a radiopharmaceutical currently in development is a synthetic version of a substance derived from scorpions–chlorotoxin. This could be a powerful…  
  • Thousands of potential cancer medicines in development
     
  • According to the Pharmaceutical Research and Manufacturers of America, a cancer medicine in the pipeline would inhibit production of a protein that may interfere with the effectiveness of chemotherapy.